Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-CRC: Image-guided cetuximab optimization in metastatic colorectal cancer
2013-002023-41Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by VU University Medical Center. Primary endpoint: Association between 89Zr-cetuximab uptake in liver and non-hepatic tumor lesions. Started Aug 2013; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-002023-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002023-41.